BSE · 524572
Pharmaids Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-09-30
- Promoter32.99%
- Public67.01%
8,720 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.11× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #30 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
| Pharmaids Pharmaceuticals Ltd.(this company) | ₹101 Cr | — | 2.1 | -15.38% | -19.84% |
AI analysis
AI-generated · google/gemini-2.5-flashPharmaids Pharmaceuticals Ltd. (524572) has a market capitalization of Rs 112 Cr. The company reported a profit margin of -42.04% and an EPS of 0. The debt-to-equity ratio stands at 0.36. As of June 30, 2026, promoter shareholding was 32.99%, with public shareholding at 67.01%.
Positives
- +The debt-to-equity ratio is 0.36, indicating relatively lower leverage.
- +The book value per share is Rs 13.51.
Negatives
- −The company reported an annual net loss of Rs 10.78 Cr in March 2025 and a quarterly net loss of Rs 1.81 Cr in March 2026.
- −The profit margin is significantly negative at -42.04%.
- −Return on equity (ROE) is -29.76% and return on capital employed (ROCE) is -20.97%.
- −The company has been placed under LT-ASM surveillance, specifically ASM Stage 1.
- −The earnings per share (EPS) is 0.
Financial performance
The company reported annual revenue of Rs 19.55 Cr in March 2025, with a net loss of Rs 10.78 Cr for the same period. Quarterly results for March 2026 showed revenue of Rs 7.18 Cr and a net loss of Rs 1.81 Cr. The EBITDA for March 2026 was -0.72.
Profitability & returns
Pharmaids Pharmaceuticals Ltd. experienced negative profitability metrics. The Roe was -29.76% and Roce was -20.97%. The company reported a negative profit margin of -42.04%, indicating that it operated at a loss relative to its revenue. The EPS as of the latest available data is 0.
Balance sheet
The book value per share is Rs 13.51. The company maintains a debt-to-equity ratio of 0.36. This indicates the proportion of debt used to finance its assets relative to shareholder equity.
Ownership & pledges
As of June 30, 2026, promoters held 32.99% of the company's shares. Public shareholding was 67.01%. There were no shares pledged by the promoters. Over the last few years, the number of shareholders has increased from 4618 in March 2018 to 8632 in June 2026.
Regulatory & surveillance
Pharmaids Pharmaceuticals Ltd. is currently under LT-ASM surveillance, specifically categorized under ASM Stage 1. This indicates that the stock has met certain criteria that warrant closer monitoring by regulatory bodies.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Pharmaids Pharmaceuticals Ltd.share price & fundamentals